Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

Université De Nantes

Université D'angers

Other

Inserm (Institut National De La Sante Et De La Recherche Medicale)

Centre Hospitalier Universitaire De Nantes

Inserm

Agnes Quemener

Hermouet, Sylvie

Feron, Delphine

Bigot-Corbel, Edith

Ariane Plet

Patricia Vusio

Erwan Mortier

Yannick Jacques

Agnès Quemener

Jérôme Bernard

Catherine Harb

Sebastien Daniel Morisseau

Dihia Meghnem

Edith Bigot-Corbel

Sylvie Hermouet

Delphine Feron

Cathy Charlier

Pierre Weigel

Adrien Herlédan

The present invention relates to the stimulation of the IL-15Rbeta/gamma signalling pathway, to thereby induce and/or stimulate the activation and/or proliferation of IL-15Rbeta/gamma-positive cells, such as NK and/or T cells. Appropriate compounds include compounds comprising at least one IL-15Rbeta/gamma binding entity, directly or indirectly linked by covalence to at least one polypeptide which contains the sushi domain of the extracellular region of an IL-15Ralpha.

IL-15Rα sushi domain—IL-15 fusion proteins

The present relates to interleukin 15 (IL-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases. In particular, the present invention relates to an IL-15 mutant polypeptide having the amino acid sequence as set forth in SEQ ID NO:1 wherein the leucine residue at position 45 is substituted by an aspartic acid residue, the asparagines residue at position 65 is substituted by a lysine residue and the leucine residue at position 69 is substituted by an arginine residue.

Uses of IL-15 antagonists for the treatment of autoimmune and inflammatory diseases

The present invention relates to specific interleukin-15 (IL-15) antagonist polypeptides and uses thereof for the treatment of inflammatory and auto-immune diseases. In particular, the present invention relates to a specific interleukin-15 (IL-15) antagonist polypeptide comprising i) a IL15-Ralpha sushi-containing polypeptide comprising an amino acid sequence having at least 80% of identity with the amino acid sequence of SEQ ID NO:1 ii) a linker and iii) an IL-polypeptide comprising the amino acid sequence having at least at least 80% of identity with the amino acid sequence of SEQ ID NO:4 provided that the glutamine (Q) residue at position 108 is mutated.

Specific interleukin-15 (IL-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases

IL-15Ralpha sushi domain&#x2014;IL-15 fusion proteins

IL-15 mutant polypeptides as IL-15 antagonists and encoding nucleic acids

The present invention concerns materials and methods for characterizing monoclonal immunoglobulin specificity of a Monoclonal Gammopathy of Undetermined Significance (MGUS) or Myeloma patients using a protein microarray comprising (a) a substrate, (b) antigens immobilized on the substrate, said antigens being selected from a defined group consisting of infectious agent antigens and/or self-antigens. In particular said protein microarray may be used to improve diagnosis, for the prognosis of myeloma or MGUS, for preventing transformation of MGUS toward myeloma, for adapting treatment of MGUS and myeloma or for monitoring the response to therapy of MGUS and myeloma patients.

Protein microarray for characterizing the specificity of the monoclonal immunoglobulins of MGUS or myeloma patients

The present invention relates to the identification of an epitope in human Interleukin-15 (IL-15) that is responsible for binding to the interleukin-15 receptor &#x3b1;-chain. Two IL-15 regions are involved in the formation of this epitope: the first region (LLELQVISL, peptide 1) corresponds to a sequence located in the B helix and the second (ENLII, peptide 2 orENLIIL, peptide 2a) to a sequence located in helix C. Muteins displaying agonist or antagonist properties are described, and may be useful as therapeutic agents.

IL-15 mutants having antagonist activity

The present invention relates to the identification of an epitope in human Interleukin-15 (IL-15) that is responsible for binding to the interleukin-15 receptor &#x3b1;-chain. Two IL-15 regions are involved in the formation of this epitope: the first region (LLELQVISL, peptide 1) corresponds to a sequence located in the B helix and the second (ENLIL, peptide 2 orENLIIL, peptide 2) to a sequence located in helix C. Muteins displaying agonist or antagonist properties are described, and may be useful as therapeutic agents.

IL-15 mutants having agonists/antagonists activity

Growing community of inventors

Nantes, France

Yannick Jacques